PROCEPT BioRobotics Corporation (PRCT) Spending and interest coverage
- R&D / revenue · 12 months: Value 23.36%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 15.69%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 23.36% | Research and development expense / revenue. Period ending 2026-06-30. $78.81M ÷ $337.34M × 100 ≈ 23.36% |
| Stock-based compensation / revenue · 12 months | 15.69% | Share-based compensation / revenue. Period ending 2026-06-30. $52.94M ÷ $337.34M × 100 ≈ 15.69% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 78.81M USD | Research and Development Expense |
| Revenue | 337.34M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 52.94M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -114.23M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $78.81M | $337.34M | $52.94M | $-114.23M | (m) | 23.36% | 15.69% | (m) | (m) |
| 2026-03-31 | $76.34M | $322.02M | $50.57M | $-109.03M | (m) | 23.71% | 15.70% | (m) | (m) |
| 2025-12-31 | $71.28M | $308.05M | $47.60M | $-103.86M | (m) | 23.14% | 15.45% | (m) | (m) |
| 2025-09-30 | $67.29M | $299.91M | $45.85M | $-92.53M | (m) | 22.44% | 15.29% | (m) | (m) |
| 2025-06-30 | $65.75M | $274.95M | $39.87M | $-91.76M | (m) | 23.91% | 14.50% | (m) | (m) |
| 2025-03-31 | $65.62M | $249.12M | $35.69M | $-96.40M | (m) | 26.34% | 14.33% | (m) | (m) |
| 2024-12-31 | $62.30M | $224.50M | $31.84M | $-96.61M | (m) | 27.75% | 14.18% | (m) | (m) |
| 2024-09-30 | $61.73M | $199.84M | $27.74M | $-106.46M | (m) | 30.89% | 13.88% | (m) | (m) |
| 2024-06-30 | $56.68M | $176.57M | $24.55M | $-109.64M | (m) | 32.10% | 13.90% | (m) | (m) |
| 2024-03-31 | $50.79M | $156.33M | $21.67M | $-108.44M | $4.15M | 32.49% | 13.86% | -26.11× | Reported |
| 2023-12-31 | $48.45M | $136.19M | $19.13M | $-109.17M | $4.00M | 35.57% | 14.05% | -27.33× | Reported |
| 2023-09-30 | $43.63M | $116.39M | $17.04M | $-104.65M | $3.74M | 37.49% | 14.64% | -28.01× | Reported |
| 2023-06-30 | $39.61M | $101.63M | $14.94M | $-101.15M | $4.17M | 38.98% | 14.70% | -24.24× | Reported |
| 2023-03-31 | $34.71M | $85.22M | $12.51M | $-93.40M | $4.65M | 40.73% | 14.68% | -20.09× | Reported |
| 2022-12-31 | $28.98M | $75.01M | $10.34M | $-80.72M | $5.18M | 38.63% | 13.78% | -15.57× | Reported |
| 2022-09-30 | $24.38M | $61.38M | $8.95M | $-72.52M | $5.76M | 39.71% | 14.58% | -12.60× | Reported |
| 2022-06-30 | $21.71M | $49.69M | $6.65M | $-63.21M | $5.77M | 43.69% | 13.38% | -10.95× | Reported |
| 2022-03-31 | $19.48M | $41.48M | $4.70M | $-58.52M | $5.77M | 46.97% | 11.33% | -10.15× | Reported |
| 2021-12-31 | $18.99M | $34.47M | $3.80M | $-54.16M | $5.81M | 55.10% | 11.01% | -9.32× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $16.27M | $7.72M | $2.17M | $-47.80M | $5.26M | 210.90% | 28.16% | -9.09× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |